Hassan Mahmudul

Cytotrait (previously Plant Organelle Technologies) focuses on the development of novel traits for food and agriculture. Our unique, proprietary approach enables the reprogramming of chloroplast and mitochondrial genomes, opening a new frontier in crop technology and helping to address the global challenges of food security and sustainable agriculture.

HotHouse Therapeutics is rewriting the future of drug discovery with BotanAI and BotanBio - our AI and plant bioengineering platforms that design and make molecules labs can’t reach. By transforming plants into sustainable biofactories, we unlock vast new chemical space, creating next-generation vaccine adjuvants and breakthrough therapeutics in days, not years. The urgency is clear: 62% of today’s medicines are natural or nature-inspired, yet conventional chemistry is slow, expensive, and environmentally harmful. As a sustainable biotech, our approach is different. Because our medicines grow in plants, they scale through vertical farming, are carbon-positive by design, and avoid destructive extraction. With deep expertise in plant science, chemistry, and AI, we’re building not just a pipeline, but a platform - delivering next-generation medicines that are greener, faster, and smarter.

Adamo Foods is a food-technology company, developing the most innovative alternatives to meat whole-cuts. We’re launching the world’s first sustainable, yet delicious steak, entirely made from fungi. “Adamo” has different meanings across the world: in Hebrew it means ‘from the ground & earth’ and in Latin ‘for the pleasure of’. Deeply rooted in these ideas, Adamo’s goal is to offer natural plant-based foods, truly grown from the ground, for the enjoyment and pleasure of everyone.

Our mission is to drug the undruggable and find solutions for unmet medical needs

MitoRx Therapeutics is a pre-clinical stage rare disease biotech company aiming to become the leading global developer of medicines arresting the progression of degenerative diseases driven by mitochondrial dysfunction, with a focus on neuromuscular disease, metabolic disease and neurodegenerative disease.

Resurrect Bio is a VC-backed plant biotech start-up, discovering how to make crops resistant to disease using gene editing. We fix the immune system of crop species. We have a unique pipeline and platform for discovering resistance genes in crops which have been defeated by pathogens and pests. We then resurrect (restore) those resistance genes to make the crop resistant again, without introducing any new DNA to the crop. We’re focussed on delivering for the world’s farmers a better way to protect their plants, using the crops own immune system instead of spraying chemicals. This will enable them to increase food production, reduce land for agriculture and help mitigate climate change.

iFAST is developing a game-changing, rapid antimicrobial susceptibility test, that will enable every patient with bacterial infections to receive the right antibiotic, on time, every time. Currently, these tests take 48-72 hours, but iFASTs tests are 10x faster, cheaper and involve less tedious manual labour. This is a $4bn market and we expect to bring our product to market at the end of next year.

GLIALIGN LIMITED is a new tissue engineering/ regenerative medicine company based in University College London School of Pharmacy, Brunswick Square, London WC1N 1AX. The Companys focus is on novel cells/materials constructs for neural tissue repair. Glialign is funded by the UCL Tech Fund, UK Innovation and Science Seed Fund and Innovate UK

Zentraxa’s proprietary technological platform, Zentide, combined with our extensive technical know-how allows us to push the boundaries of what can be achieved with synthetic biopolymers. We specialise in the design, production and testing of complex novel peptides and, as a result of our Zentide platform, can circumvent the previously existing bio-design limits of conventional peptide synthesis with one universal process.

Nemesis Bioscience is a biopharmaceutical company developing Nemesis Symbiotics© - DNA therapeutics administered before antibiotics to inactivate resistance in bacterial pathogens. These Nemesis Symbiotics© will make existing antibiotics work again, prevent the spread of resistance genes and so also protect the efficacy of new antibiotics. The technology is applicable to all antibiotic classes, all known resistance mechanisms and all bacteria. Other applications include reduction of chemotherapeutic toxicity, inactivation of virulence factors and in vivo synthesis of biofuels and therapeutics. The company was awarded the King’s College, Cambridge Entrepreneurship Award for 2014 and has filed patent applications internationally on its inventions. NEMESIS BIOSCIENCE LTD is a biotechnology company based on th Babraham Research Campus, Cambridge, CB22 3AT, UK

Future Planet is the impact-led, global venture capital firm built to back growth companies emerging from the founders and science from the worlds top universities. Through a unique series of partnerships and relationships around leading universities, Future Planet has an unrivalled global level of access to entrepreneurs and businesses profitably solving the worlds greatest challenges in Climate Change, Education, Health, Sustainable Growth & Security. Our mission is not simply to deliver excellent returns but to create a lasting impact: by connecting the worlds largest investors with its best minds, we believe we can profitably address the greatest challenges that humanity faces today. The Future Planet Fund has been designed in close conjunction with sophisticated investors in order to provide multi-stage access to start-ups, spin-outs and growing companies, at a scale large enough to suit major sovereign wealth funds and similar institutions.

Cytotrait (previously Plant Organelle Technologies) focuses on the development of novel traits for food and agriculture. Our unique, proprietary approach enables the reprogramming of chloroplast and mitochondrial genomes, opening a new frontier in crop technology and helping to address the global challenges of food security and sustainable agriculture.

HotHouse Therapeutics is rewriting the future of drug discovery with BotanAI and BotanBio - our AI and plant bioengineering platforms that design and make molecules labs can’t reach. By transforming plants into sustainable biofactories, we unlock vast new chemical space, creating next-generation vaccine adjuvants and breakthrough therapeutics in days, not years. The urgency is clear: 62% of today’s medicines are natural or nature-inspired, yet conventional chemistry is slow, expensive, and environmentally harmful. As a sustainable biotech, our approach is different. Because our medicines grow in plants, they scale through vertical farming, are carbon-positive by design, and avoid destructive extraction. With deep expertise in plant science, chemistry, and AI, we’re building not just a pipeline, but a platform - delivering next-generation medicines that are greener, faster, and smarter.

Adamo Foods is a food-technology company, developing the most innovative alternatives to meat whole-cuts. We’re launching the world’s first sustainable, yet delicious steak, entirely made from fungi. “Adamo” has different meanings across the world: in Hebrew it means ‘from the ground & earth’ and in Latin ‘for the pleasure of’. Deeply rooted in these ideas, Adamo’s goal is to offer natural plant-based foods, truly grown from the ground, for the enjoyment and pleasure of everyone.

Our mission is to drug the undruggable and find solutions for unmet medical needs

MitoRx Therapeutics is a pre-clinical stage rare disease biotech company aiming to become the leading global developer of medicines arresting the progression of degenerative diseases driven by mitochondrial dysfunction, with a focus on neuromuscular disease, metabolic disease and neurodegenerative disease.